_1777370220974_847775619.png&w=48&q=75){kind=small}
US Peptides Outlook Clarifies
An FDA advisory committee will review seven experimental peptides to determine if they should be added to the list allowing licensed compounding pharmacies to dispense them. These peptides, used for purposes like wound healing, inflammation, and obesity, are currently unapproved and lack extensive safety data. The committee's decision could influence the regulation and accessibility of these peptides, amid concerns about safety and limited clinical research.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)